Welcome to our dedicated page for Burning Rock Biotech American Depositary Shares news (Ticker: BNR), a resource for investors and traders seeking the latest updates and insights on Burning Rock Biotech American Depositary Shares stock.
Burning Rock Biotech Limited (NASDAQ: BNR, LSE: BNR) is a pioneering cancer diagnostics company headquartered in China, established in 2014. The company is dedicated to leveraging next-generation sequencing (NGS) technology to advance precision oncology. This innovative approach aids in the selection of cancer therapies and the early detection of cancer, enhancing treatment outcomes and patient care.
Burning Rock operates through three primary segments: Central laboratory business, In-hospital business, and Pharma research and development services. The central laboratory business generates the majority of the company’s revenue. The company’s suite of products includes Pan-HEME, OncoScreen-WES, brPROPHET, and OncoScreen Plus, which provide comprehensive cancer profiling and support personalized treatment plans.
In a strategic move to comply with NASDAQ Listing Rules 5810(c)(3)(A), Burning Rock must meet the minimum bid price requirement by June 26, 2024. Should the company's ADSs maintain a closing bid price of at least US$1.00 for ten consecutive business days, NASDAQ will confirm compliance, closing the matter. Failing this, the company might be granted an additional 180-day period to meet the requirement.
Recently, Burning Rock announced an ADS Ratio Change, equivalent to a one-for-ten reverse ADS split, effective immediately. Certificate holders must surrender existing ADSs for the new ratio, while uncertificated ADSs will auto-adjust. This change is expected to proportionally increase the ADS price, although no guarantees are provided.
Burning Rock’s mission, “Guard Life via Science,” underscores its commitment to advancing cancer diagnostics and treatment through scientific innovation. The company continues to make significant strides in cancer early detection, moving beyond proof-of-concept R&D into clinical validation.
For more information, visit ir.brbiotech.com.
Burning Rock Biotech Limited (NASDAQ: BNR, LSE: BNR) announced plans to release its unaudited financial results for Q1 2023 on May 30, 2023, before U.S. market opens. Management will hold a conference call at 8:00 a.m. ET on the same day. The company anticipates moderate revenue growth year-over-year, driven by a strong rebound in March, reversing previous declines in January-February. March 2023 total test volumes increased by approximately 29% year-over-year, attributed mainly to growth in the in-hospital channel. Investors can register for the call and access a live webcast on the company’s investor relations website.
Burning Rock Biotech Limited (NASDAQ: BNR), focused on next-generation sequencing technology for precision oncology, filed its Annual Report on Form 20-F for the fiscal year ending December 31, 2022, with the U.S. SEC on April 21, 2023. The report is accessible on both the SEC website and the company's own site.
Burning Rock's business segments include NGS-based therapy selection testing for late-stage cancer patients and cancer early detection, which has advanced to the clinical validation phase. The company's mission remains centered on enhancing cancer care through scientific innovation.
Burning Rock Biotech Limited (NASDAQ: BNR) reported its financial results for the fourth quarter and full year 2022. The company recorded revenues of RMB142.2 million (US$20.6 million) for Q4 2022, a 3.5% decrease compared to Q4 2021, mainly due to COVID-19 impacts. For full-year 2022, revenues rose 10.9% to RMB563.2 million (US$81.7 million). The net loss for Q4 2022 was RMB216.2 million (US$31.4 million), improved from RMB251.1 million in Q4 2021. The company achieved a significant milestone with its Early Detection OverCTM test receiving Breakthrough Device Designation from the FDA. 2023 revenue guidance suggests an expected growth of approximately 20% over 2022.
Burning Rock Biotech Limited (NASDAQ: BNR) has announced plans to release its unaudited financial results for the fourth quarter and full year 2022 prior to the U.S. market opening on March 28, 2023. Following the results, management will host a conference call at 8:00 a.m. ET (8:00 p.m. Hong Kong time) to discuss the financial outcomes. The company focuses on next generation sequencing (NGS) technology in precision oncology, which includes therapy selection testing for late-stage cancer patients and early cancer detection now in clinical validation. Investors can pre-register for the conference call through the provided link.
FAQ
What is the current stock price of Burning Rock Biotech American Depositary Shares (BNR)?
What is the market cap of Burning Rock Biotech American Depositary Shares (BNR)?
What is Burning Rock Biotech Limited?
What are the main business segments of Burning Rock?
How does Burning Rock generate most of its revenue?
What recent compliance measure did Burning Rock announce?
What is the ADS Ratio Change for Burning Rock?
What products does Burning Rock offer?
What is the mission of Burning Rock Biotech Limited?
Where can I find more information about Burning Rock?
What does the ADS ratio change mean for investors?
Are there any changes to Burning Rock's Class A ordinary shares?
